Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
QLGN | US
0.02
9.15%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.18
0.17
0.18
0.16
Qualigen Therapeutics Inc. a biotechnology company focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack a patent-protected rapid onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247 an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers including liquid and solid tumors; QN-165 a drug candidate for the potential broad-spectrum treatment of infectious diseases such as COVID-19; RAS-F a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system a therapeutic device to remove circulating tumor cells viruses inflammation factors and immune checkpoints. Qualigen Therapeutics Inc. was founded in 1996 and is based in Carlsbad California.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
65.2%1 month
52.6%3 months
67.7%6 months
199.2%-
-
0.41
-0.39
3.12
-0.05
0.68
-
-8.33M
4.93M
4.93M
-
-
-
13.70
-841.66
0.36
0.40
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.03
Range3M
0.15
Rel. volume
2.77
Price X volume
81.69K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PALISADE BIO INC | PALI | Biotechnology | 3.91 | 5.41M | 0.51% | n/a | 5.06% |
ERNA | ERNA | Biotechnology | 0.9899 | 5.36M | -2.95% | n/a | -577.12% |
XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 1.71 | 5.15M | -9.04% | n/a | 3.09% |
BIONOMICS LIMITED/FI | BNOX | Biotechnology | 0.2955 | 5.12M | -1.53% | n/a | 0.59% |
180 Life Sciences Corp | ATNF | Biotechnology | 4.97 | 5.10M | -1.19% | n/a | -105.81% |
Molecular Templates Inc | MTEM | Biotechnology | 0.75 | 4.94M | 0.00% | n/a | 155.07% |
Enveric Biosciences Inc | ENVB | Biotechnology | 0.538 | 4.80M | 20.33% | n/a | 0.00% |
CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 0.146 | 4.69M | 19.67% | n/a | -2.87% |
Azitra Inc | AZTR | Biotechnology | 0.61 | 4.65M | 0.00% | 0.01 | 41.86% |
ADTX | ADTX | Biotechnology | 1.09 | 4.60M | 3.81% | n/a | 122.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.05 | 0.53 | Cheaper |
Ent. to Revenue | 0.68 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.41 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 67.68 | 72.80 | Par |
Debt to Equity | -0.39 | -1.23 | Expensive |
Debt to Assets | 3.12 | 0.25 | Expensive |
Market Cap | 4.93M | 3.66B | Emerging |